Study Results Demonstrate Early Cardio-Renal Effects of AstraZeneca’s Farxiga

Recently presented and published study results have demonstrated the ability of AstraZeneca’s Farxiga on reducing the progression of kidney disease or renal death in type-2 diabetes, it was announced in a June 10, 2019 press release.

The pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial were presented at the American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, and simultaneously published in The Lancet Diabetes & Endocrinology. The data demonstrated that Farxiga provided a 47% reduction in the relative risk of the composite renal-specific outcome of kidney function decline, end-stage renal disease, or renal death when compared with placebo.

Additionally, the treatment was found to lower the relative risk of cardio-renal composite of kidney function decline, end-stage renal disease, or renal or cardiovascular death by 24% compared to placebo.

“Heart failure and renal diseases are two of the most common and early complications experienced by people living with type-2 diabetes, and are too often overlooked,” said Elisabeth Björk, senior vice-president, head of late-stage development, cardiovascular, renal, and metabolism, biopharmaceuticals R&D, AstraZeneca in the release. “They contribute to a growing economic burden on the global healthcare system and can lead to fatal outcomes for patients. These data continue to offer clinically relevant evidence of the early cardio-renal effects of Farxiga.”

The pre-specified analysis comprised 17,160 patients with type-2 diabetes and predominantly preserved renal function, irrespective of underlying atherosclerotic cardiovascular disease.

Source: AstraZeneca